Woodcock Encourages Patient Groups To Take Lead To Speed Regulatory Process, Development
This article was originally published in The Pink Sheet Daily
Medical and patient communities can help make up for FDA’s resource gaps by developing PRO standards and benefit-risk frameworks for specific diseases, FDA drug chief says.
You may also be interested in...
Conflict among groups with conditions both included and not included in the preliminary list of public meeting topics prompts FDA to reiterate that the diseases will be selected because better clinical measures are needed, not because the agency will prioritize them over others.
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.
Breast cancer meeting highlights challenges of patient-focused drug development as breast cancer patients ask for trials to better identify characteristics of super-responders so patients can make more informed risk-benefit decisions.